EP08.02-015 The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center

The management of stage 4 non-squamous non-small cell lung cancer (NSCLC) requires tumor genotyping to identify driver mutations that indicate the use of small molecules as first line therapy. Such mutations have traditionally been characterized by genetic study of biopsied tumor tissues. Recently, the “liquid biopsy”, a non-invasive genomic analysis of circulating tumor DNA, has been deemed a suitable complementary method to identify actionable mutations in NSCLC patients. At our community-based academic medical system in suburban Philadelphia, we performed a retrospective chart review study to assess the impact of adding liquid biopsies to tissue molecular testing as part of the initial genetic characterization of stage IV non-squamous NSCLC.